Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CETP | P11597 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344683 | 1.00 | USP2 (0.50) | USP2DNM1ALDH1A1CNR1CNR2 | |
| SCHEMBL27547339 | 1.00 | USP2 (0.50) | USP2DNM1ALDH1A1CNR1CNR2 | |
| SCHEMBL1752697 | 1.00 | USP2 (0.50) | USP2DNM1ALDH1A1CNR1CNR2 | |
| SCHEMBL113020 | 1.00 | USP2 (0.50) | USP2DNM1ALDH1A1CNR1CNR2 | |
| SCHEMBL27710760 | 0.98 | USP2 (0.47) | USP2DNM1ALDH1A1CNR1CNR2 | |
| SCHEMBL4248982 | 0.91 | USP2 (0.39) | USP2DNM1ALDH1A1CNR1CNR2 | |
| SCHEMBL28154318 | 0.87 | ALDH1A1 (0.41) | USP2DNM1ALDH1A1CNR1CNR2 | |
| SCHEMBL10696347 | 0.85 | DNM1 (0.45) | USP2DNM1HTTMAPTSPHK1 | |
| SCHEMBL4621765 | 0.85 | USP2 (0.44) | USP2DNM1ALDH1A1CNR1CNR2 | |
| SCHEMBL20788829 | 0.83 | USP2 (0.50) | USP2DNM1ALDH1A1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002541238-A | — | — | 2002-12-03 | — | — | JP | claimed |
| EP-1183228-A2 | ESTERS OF L-CARNITINE OR ALKANOYL L-CARNITINES | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2002-03-06 | — | — | EP | claimed |
| WO-2000061543-A2 | ESTERS OF L-CARNITINE OR ALKANOYL L-CARNITINES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2000-10-19 | — | — | WO | claimed |
| WO-2023077110-A2 | MANAGEMENT OF SKIN AILMENTS | SHAMSUDDIN ABULKALAM M (US) | 2023-05-04 | — | — | WO | disclosed |
| CN-111848368-A | Method for improving purity of batyl alcohol in shark liver oil | 浙江工商大学 | 2020-10-30 | — | — | CN | disclosed |
| US-9968622-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2018-05-15 | — | — | US | disclosed |
| US-20170246197-A1 | High-Purity Phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2017-08-31 | — | — | US | disclosed |
| US-9566288-B2 | High-purity phospholipids | VASCULAR BIOGENICS LTD. (IL) | 2017-02-14 | — | — | US | disclosed |
| EP-2125838-B1 | IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | VASCULAR BIOGENICS LTD (IL) | 2016-05-11 | — | — | EP | disclosed |
| EP-2604614-B1 | Oxidized phospholipids | VASCULAR BIOGENICS LTD (IL) | 2016-03-09 | — | — | EP | disclosed |
| CN-102040621-B | Lipid oxide and the application in treatment inflammatory diseases thereof | CANALIS-HAEMALIS BIOGROWTH LTD. (IL) | 2016-01-20 | — | — | CN | disclosed |
| WO-2006006161-A2 | IMPROVED PROCESS FOR THE PREPARATION OF OXIDIZED PHOSPHOLIPIDS | VASCULAR BIOGENICS LTD. (IL) | 2006-01-19 | — | — | WO | disclosed |
| US-20050272813-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2005-12-08 | — | — | US | disclosed |
| US-6838452-B2 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2005-01-04 | — | — | US | disclosed |
| WO-2004106486-A2 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | VASCULAR BIOGENICS LTD. (IL) | 2004-12-09 | — | — | WO | disclosed |
| US-20040106677-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. (IL) | 2004-06-03 | — | — | US | disclosed |
| US-20030225035-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | VASCULAR BIOGENICS LTD. | 2003-12-04 | — | — | US | disclosed |
| EP-1341543-A2 | METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS | Vascular Biogenics Ltd. (IL) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002041827-A9 | METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS | VASCULAR BIOGENICS LTD (IL) | 2003-05-30 | — | — | WO | disclosed |
| WO-2002041827-A2 | METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS | VASCULAR BIOGENICS LTD. (IL) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272813-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | PHOSPHO1, GPX4, SGMS1 | USP2 1194/4885DNM1 1248/4885ALDH1A1 2337/4885 |
| US-20170246197-A1 | High-Purity Phospholipids | PHOSPHO1, SGMS1, SGMS2 | USP2 4148/4885DNM1 2005/4885ALDH1A1 2385/4885 |
| US-20030225035-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | PHOSPHO1, GPX4, SGMS1 | USP2 1194/4885DNM1 1248/4885ALDH1A1 2337/4885 |
| US-20040106677-A1 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis | PHOSPHO1, GPX4, SGMS1 | USP2 1194/4885DNM1 1248/4885ALDH1A1 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.